Newsbenzinga
Anavex Life Sciences Reports Preliminary Q2 Net Loss Of $0.06 Per Share vs. $0.13 A Year Ago; $127.4M Cash Funds Operations Into Mid-To-Late Fiscal 2028
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…